Racemic Epinephrine: Uses, Dosage, and Side Effects

Racemic epinephrine is an adrenergic medication used primarily to reduce swelling of the upper airway. Its strong vasoconstricting effects make it useful in conditions such as croup, postextubation laryngeal edema, stridor, and selected inhalation injuries. It may also help control localized airway bleeding.

Although racemic epinephrine can produce bronchodilation through beta-receptor stimulation, its most important respiratory effect is alpha-mediated vasoconstriction.

Because the medication acts quickly but has a relatively short duration, close assessment and continued monitoring are important after administration.

What Is Racemic Epinephrine?

Racemic epinephrine is a sympathomimetic medication that stimulates adrenergic receptors throughout the body. In respiratory care, it is most commonly administered by aerosol to patients who have significant swelling of the upper airway.

Unlike selective beta-2 agonists such as albuterol, racemic epinephrine stimulates both alpha and beta adrenergic receptors. This broad receptor activity gives the medication several physiologic effects.

The most important effects include:

• Vasoconstriction of swollen airway tissues
• Reduction of mucosal and submucosal edema
• Relaxation of bronchial smooth muscle
• Increased heart rate and cardiac contractility
• Increased systemic vascular resistance and blood pressure

The strong vasoconstricting effect is particularly useful when airway obstruction is caused by tissue swelling rather than bronchospasm.

For example, a patient who develops inspiratory stridor after extubation may have laryngeal edema. In this situation, racemic epinephrine can constrict blood vessels within the swollen tissue and temporarily increase the functional diameter of the airway.

Meaning of Racemic Epinephrine

The term racemic refers to a mixture containing two stereochemical forms, or isomers, of epinephrine.

Racemic epinephrine contains:

• R-isomer, also known as the levo form
• S-isomer, also known as the dextro form

The R-isomer is primarily responsible for adrenergic receptor activity, while the S-isomer has very little pharmacologic activity. This differs from naturally occurring epinephrine, which primarily consists of the biologically active form.

The distinction is important because racemic epinephrine has traditionally been prepared at concentrations specifically intended for aerosol administration. A commonly used formulation is a 2.25% solution.

Despite the presence of two isomers, the active component produces the familiar alpha- and beta-adrenergic effects associated with epinephrine.

Pharmacologic Classification

Racemic epinephrine is classified as an adrenergic or sympathomimetic medication. It is also categorized as a catecholamine.

Catecholamines contain a catechol structure attached to an amine side chain. This chemical structure allows them to interact effectively with adrenergic receptors, but it also makes them susceptible to rapid metabolism.

Racemic epinephrine is generally considered an ultrashort-acting adrenergic medication because its clinical effects occur quickly and generally last for only a short period. Its rapid onset is advantageous during acute airway obstruction, but its brief duration means that improvement following treatment may not persist.

Adrenergic Receptors

Understanding the effects of racemic epinephrine requires an understanding of adrenergic receptors. The three receptor types most relevant to its respiratory and cardiovascular effects are alpha-1, beta-1, and beta-2 receptors.

Alpha-1 Receptors

Alpha-1 receptors are located in vascular smooth muscle. Stimulation causes vasoconstriction. In the respiratory tract, this effect is particularly important in swollen mucosal tissue. When blood vessels constrict, vascular engorgement decreases and less fluid remains within the tissue.

The result is a reduction in edema. For racemic epinephrine, this alpha-1 effect is one of the primary reasons the medication is used for upper-airway obstruction.

Beta-1 Receptors

Beta-1 receptors are concentrated primarily in the heart. Stimulation can produce:

• Increased heart rate
• Increased force of contraction
• Increased myocardial oxygen demand

Note: These cardiac effects are not usually the desired response when racemic epinephrine is administered for upper-airway swelling. Instead, they represent an important source of adverse effects.

Beta-2 Receptors

Beta-2 receptors are located in bronchial smooth muscle. Stimulation causes smooth-muscle relaxation and bronchodilation.

Racemic epinephrine can therefore produce some bronchodilator activity. However, it is not generally preferred for routine treatment of lower-airway bronchospasm because newer medications such as albuterol provide stronger beta-2 selectivity and typically produce fewer cardiovascular effects.

Mechanism of Action

The main therapeutic effect of racemic epinephrine in upper-airway disease results from vasoconstriction. Inflammation increases blood flow and vascular permeability within affected tissues. Fluid then accumulates in the mucosa and submucosa, causing the tissue to swell.

Within the upper airway, even a relatively small amount of swelling may significantly decrease airway diameter. This is particularly important in children because pediatric airways are already smaller than adult airways.

When racemic epinephrine reaches the swollen mucosa, alpha-receptor stimulation causes local blood vessels to constrict. This decreases vascular congestion and reduces the amount of fluid present within the tissues.

As swelling decreases, the functional airway diameter increases and resistance to airflow decreases. The medication may simultaneously stimulate beta-2 receptors and produce some bronchodilation, but this effect is usually secondary when the drug is being used for croup, laryngeal edema, or postextubation stridor.

Racemic Epinephrine and Airway Resistance

Airway resistance increases dramatically as airway diameter decreases. This relationship explains why upper-airway swelling can become dangerous very quickly, especially in infants and young children.

Edematous tissue projects inward toward the lumen because the surrounding structures limit outward expansion. Even modest mucosal thickening can therefore create significant obstruction.

Clinical findings may include:

• Inspiratory stridor
• Retractions
• Increased work of breathing
• Tachypnea
• Hoarseness
• Decreased air movement
• Agitation
• Cyanosis in severe cases

Note: By decreasing mucosal edema, racemic epinephrine may increase airway diameter enough to produce rapid improvement in airflow. However, the underlying inflammatory condition often remains present. Once the vasoconstricting effect wears off, airway swelling may return.

Onset, Peak, and Duration

Racemic epinephrine has a rapid onset of action. The approximate pharmacologic characteristics include:

• Onset: 3 to 5 minutes
• Peak effect: approximately 5 to 20 minutes
• Duration: approximately 30 minutes to 2 hours

Some sources describe the duration as approximately one to two hours. The exact response varies depending on the patient, severity of disease, route of administration, and dose.

Its short duration is clinically important. A patient may improve significantly after treatment but develop recurrent stridor or respiratory distress later as the medication wears off. For this reason, continued assessment is necessary after administration.

Metabolism

Racemic epinephrine is a catecholamine and is rapidly metabolized by enzymes within the body. One important enzyme is catechol O-methyltransferase, commonly abbreviated COMT.

COMT modifies the catechol structure and contributes to the rapid inactivation of epinephrine. This rapid metabolism is one reason racemic epinephrine has such a short duration.

By comparison, many modern beta-2 agonists have chemical modifications that make them less vulnerable to rapid metabolism, allowing them to provide bronchodilation for four hours, six hours, 12 hours, or even longer. Racemic epinephrine therefore remains most useful when an immediate short-term effect is desired.

Racemic Epinephrine for Croup

Croup is one of the most common conditions associated with aerosolized racemic epinephrine. Croup, also called laryngotracheitis or laryngotracheobronchitis, is usually caused by a viral infection that produces inflammation of the upper airway.

Swelling is especially important in the subglottic region. Children with croup commonly develop:

• Barking or seal-like cough
• Inspiratory stridor
• Hoarseness
• Retractions
• Tachypnea
• Increased work of breathing

Note: Early symptoms may include rhinorrhea, low-grade fever, and mild upper-respiratory symptoms. As airway narrowing becomes more severe, stridor may occur at rest and respiratory distress may become more pronounced.

Why Racemic Epinephrine Helps Croup

The primary problem in croup is inflammation and edema of the upper airway. Racemic epinephrine stimulates alpha receptors within the swollen mucosa, producing vasoconstriction and reducing edema.

As the edema decreases, airway caliber improves and stridor may lessen. Clinical improvement can occur within several minutes.

Systemic corticosteroids are also commonly used because they address the underlying inflammatory process and provide longer-lasting effects. Racemic epinephrine therefore provides rapid symptom relief while anti-inflammatory medications help reduce the underlying inflammation over a longer period.

Monitoring After Treatment

Because the effects of racemic epinephrine are short-lived, the child should continue to be observed after treatment.

Clinicians should assess:

• Stridor
• Respiratory rate
• Retractions
• Work of breathing
• Air movement
• Oxygen saturation
• Mental status
• Heart rate

Note: Persistent or worsening symptoms may indicate the need for additional respiratory support. If significant obstruction continues despite medical therapy, options such as heliox or advanced airway management may be considered depending on the clinical situation.

Postextubation Laryngeal Edema

Another major indication for racemic epinephrine is laryngeal edema following extubation. An endotracheal tube can irritate the laryngeal mucosa, especially when the tube has been in place for an extended period.

After the tube is removed, swelling may narrow the upper airway. The classic clinical sign is inspiratory stridor.

Other findings may include:

• Hoarseness
• Throat tightness
• Tachypnea
• Increased respiratory effort
• Suprasternal retractions
• Decreased air movement
• Anxiety or agitation

Note: Racemic epinephrine may be administered by nebulizer to reduce the edema.

The Cuff-Leak Test

Before extubation, clinicians may perform a cuff-leak assessment in patients believed to be at increased risk of postextubation airway obstruction. The cuff is deflated and the amount of air passing around the endotracheal tube is evaluated.

The presence of an adequate leak suggests that there is enough space between the tube and surrounding airway tissue for air to pass. A limited or absent cuff leak may raise concern for significant laryngeal edema.

A cuff leak of approximately 15% or greater has historically been associated with a lower likelihood of significant postextubation obstruction, although the test does not perfectly predict which patients will develop stridor. The cuff-leak test is therefore one part of the overall clinical assessment.

Preparing for Extubation

When a patient is considered at risk for upper-airway edema, appropriate equipment should be immediately available before removing the endotracheal tube.

This may include:

• Oxygen-delivery equipment
• Suction equipment
• Bag-valve-mask device
• Intubation equipment
• Appropriate endotracheal tubes
• Small-volume nebulizer
• Racemic epinephrine
• Normal saline

Note: Preparation is important because postextubation obstruction may progress rapidly. Racemic epinephrine can reduce swelling, but severe airway obstruction may still require reintubation.

Postextubation Stridor Treatment

When postextubation stridor occurs and laryngeal edema is suspected, racemic epinephrine may be administered by nebulizer.

A commonly referenced dose is:

0.5 mL of 2.25% racemic epinephrine diluted with approximately 3 mL of normal saline.

Cool humidified oxygen may also be provided.

The patient’s respiratory status should then be reassessed.

Improvement in stridor and air movement suggests a favorable response, but the patient still requires observation because the medication’s effects may diminish within a relatively short period.

Note: Severe or progressive obstruction requires escalation of airway management.

Racemic Epinephrine and Epiglottitis

Epiglottitis is an acute inflammatory condition involving the epiglottis and surrounding supraglottic structures. Severe swelling can quickly produce critical upper-airway obstruction.

Typical findings may include:

• High fever
• Severe sore throat
• Drooling
• Muffled voice
• Inspiratory stridor
• Respiratory distress
• Tripod positioning

Unlike croup, a classic barking cough may be absent. Airway management is the main concern in severe epiglottitis. Racemic epinephrine may help reduce laryngeal swelling through local vasoconstriction, but it should never be considered a substitute for securing a threatened airway.

Patients with severe epiglottitis may require intubation. When a patient who has been intubated for epiglottitis is later extubated, racemic epinephrine may be kept available at the bedside in case upper-airway edema or stridor develops.

Racemic Epinephrine and Bronchiolitis

Bronchiolitis primarily affects infants and involves inflammation of the small airways. Respiratory syncytial virus is a common cause. Inflammation, mucosal edema, secretions, and cellular debris contribute to airway narrowing.

Symptoms may include:

• Wheezing
• Tachypnea
• Retractions
• Cough
• Hypoxemia
• Respiratory distress

Routine bronchodilator therapy is generally not recommended for every patient with bronchiolitis because the obstruction frequently results from edema and secretions rather than reversible smooth-muscle bronchospasm.

However, selected patients may receive a trial of inhaled bronchodilator therapy, including racemic epinephrine. Treatment should only be continued when objective improvement occurs.

This might include improvement in:

• Respiratory rate
• Work of breathing
• Air movement
• Wheezing
• Oxygenation

Note: The medication should not automatically be administered repeatedly when no clinical benefit is demonstrated.

Inhalation Injuries

Smoke, steam, superheated air, and irritating chemicals can damage upper-airway tissues. Inflammation may develop quickly and produce significant mucosal edema.

Possible findings include:

• Hoarseness
• Stridor
• Soot around the mouth or nose
• Facial burns
• Respiratory distress
• Difficulty swallowing
• Progressive airway obstruction

Racemic epinephrine may be used in selected cases when mucosal swelling contributes to airway narrowing. However, inhalation injuries can progress rapidly.

When significant airway edema is anticipated, early airway stabilization may be necessary rather than relying solely on aerosol medications.

Bronchoscopy and Airway Bleeding

Racemic epinephrine can also be used to help control localized airway bleeding. During bronchoscopy, tissue may be biopsied for diagnostic evaluation. Biopsy can injure small blood vessels and produce bleeding.

Local administration of racemic epinephrine stimulates alpha receptors and produces vasoconstriction. This decreases blood flow to the affected tissue and may help reduce bleeding.

The same pharmacologic property responsible for shrinking swollen mucosal tissue therefore makes racemic epinephrine useful as a local hemostatic agent.

Nasotracheal Intubation

Racemic epinephrine may also be applied to the nasal mucosa before nasotracheal intubation. The nasal passages contain numerous blood vessels and may bleed when an endotracheal tube is advanced through the nose.

A topical vasoconstrictor can reduce vascular engorgement before insertion.

This may:

• Increase the available nasal passage diameter
• Reduce mucosal swelling
• Decrease nasal bleeding

Note: Phenylephrine may also be used for this purpose. The principle is the same: alpha-mediated vasoconstriction reduces blood flow and swelling within the nasal mucosa.

Racemic Epinephrine vs. Albuterol

Racemic epinephrine and albuterol are both adrenergic medications, but their clinical roles differ significantly. Albuterol primarily stimulates beta-2 receptors. Its major effect is bronchodilation.

It is commonly used for conditions involving lower-airway bronchospasm, including:

• Asthma
• Chronic obstructive pulmonary disease
• Reversible bronchoconstriction

Racemic epinephrine stimulates alpha, beta-1, and beta-2 receptors. Its major advantage is therefore not simply bronchodilation but its ability to produce vasoconstriction.

A useful distinction is:

• Wheezing from bronchospasm: consider a beta-2 agonist such as albuterol
• Inspiratory stridor from upper-airway edema: consider racemic epinephrine

Note: This distinction is particularly important on respiratory therapy examinations.

Racemic Epinephrine vs. Systemic Epinephrine

Aerosolized racemic epinephrine should also be distinguished from systemic epinephrine. Systemic epinephrine is used when widespread adrenergic activity is necessary. The classic example is anaphylaxis.

Anaphylaxis may cause:

• Hypotension
• Bronchospasm
• Laryngeal edema
• Urticaria
• Cardiovascular collapse

In this setting, local treatment of the upper airway is not sufficient. Systemic epinephrine is necessary to support vascular tone, improve blood pressure, produce bronchodilation, and reduce widespread allergic effects.

Nebulized racemic epinephrine may reduce localized laryngeal edema, but it does not replace systemic epinephrine when anaphylaxis is present.

Dosage and Administration

A commonly used racemic epinephrine concentration is 2.25%.

Typical aerosol doses range from:

0.25 to 0.5 mL of a 2.25% solution.

The medication is generally diluted with normal saline before administration through a small-volume nebulizer.

A commonly referenced treatment is:

0.5 mL of 2.25% racemic epinephrine mixed with approximately 3 mL of normal saline.

Exact dosing depends on the patient’s age, condition, severity of symptoms, institutional protocol, and medical orders.

Dosage Calculation

A 2.25% solution contains:

2.25 g per 100 mL

Converting grams to milligrams gives:

2,250 mg per 100 mL

Dividing by 100 gives:

22.5 mg/mL

Therefore:

• 0.25 mL contains approximately 5.63 mg
• 0.5 mL contains approximately 11.25 mg
• 0.6 mL contains approximately 13.5 mg

Note: Understanding percentage concentrations is useful because racemic epinephrine frequently appears in medication-calculation questions.

Adverse Effects

Because racemic epinephrine stimulates multiple adrenergic receptor types, systemic effects can occur.

Possible adverse effects include:

• Tachycardia
• Palpitations
• Increased blood pressure
• Tremor
• Headache
• Nervousness
• Irritability
• Insomnia

Cardiovascular effects are especially important because beta-1 stimulation increases heart rate and cardiac workload. Alpha-mediated vasoconstriction can also increase blood pressure.

Although aerosol administration generally produces less systemic stimulation than injectable epinephrine, monitoring remains necessary.

Monitoring During Treatment

Before administering racemic epinephrine, baseline assessment may include:

• Heart rate
• Respiratory rate
• Blood pressure
• Oxygen saturation
• Breath sounds
• Presence and severity of stridor
• Work of breathing

During and after treatment, these findings should be reassessed. A significant increase in heart rate may indicate excessive adrenergic stimulation.

A general guideline used with aerosolized adrenergic medications is to stop treatment when the pulse increases approximately 20% or more above the pretreatment value, particularly when accompanied by other adverse effects. Institutional policies and patient-specific circumstances should also guide treatment decisions.

Short Duration and Recurrence of Symptoms

One of the most important concepts surrounding racemic epinephrine is that clinical improvement may be temporary. The medication constricts swollen blood vessels but does not instantly eliminate the underlying inflammatory process.

As the medication wears off, vasodilation may return and the airway may become swollen again. This is why patients with croup or postextubation stridor should continue to be observed even after they initially improve.

Repeated assessment should focus on:

• Stridor
• Respiratory effort
• Air movement
• Oxygenation
• Mental status
• Heart rate
• Signs of fatigue

Note: Worsening symptoms may indicate that the underlying obstruction is progressing.

Racemic Epinephrine Is Not Definitive Airway Management

Racemic epinephrine can improve upper-airway edema, but it cannot guarantee airway patency.

Severe upper-airway obstruction may require:

• Positive-pressure ventilation
• Heliox
• Noninvasive respiratory support in selected situations
• Endotracheal intubation
• Emergency airway procedures in extreme cases

This is especially important when a patient demonstrates declining mental status, severe respiratory distress, poor air movement, hypercapnia, respiratory acidosis, or progressive hypoxemia.

Medication should never delay definitive airway management when respiratory failure is developing.

Storage and Stability

Racemic epinephrine is chemically sensitive to environmental exposure. Catecholamines can degrade when exposed to:

• Heat
• Light
• Air

Oxidation can produce inactive compounds known as adrenochromes. For this reason, racemic epinephrine may be stored in an amber-colored container or protected from light.

Oxidation may also cause visible discoloration. Condensed medication within nebulizer tubing can develop a pink or pinkish-brown appearance.

Respiratory secretions may occasionally appear slightly pink after treatment for the same reason. This discoloration may represent chemical oxidation rather than blood.

Clinical Recognition

Recognizing the type of airway obstruction is essential when determining whether racemic epinephrine is appropriate. Inspiratory stridor suggests upper-airway narrowing.

Common conditions associated with stridor include:

• Croup
• Postextubation laryngeal edema
• Epiglottitis
• Foreign-body obstruction
• Laryngeal trauma
• Inhalation injury

Racemic epinephrine is useful when the narrowing is caused by mucosal edema. By contrast, expiratory wheezing generally suggests lower-airway obstruction and is more commonly treated with a selective beta-2 agonist.

Identifying whether the patient’s problem is primarily swelling, bronchospasm, secretions, or a fixed obstruction helps determine the appropriate treatment.

Key Points to Remember

Racemic epinephrine is primarily associated with rapid reduction of airway edema.

Important concepts include:

• It stimulates alpha and beta adrenergic receptors.
• Alpha-1 stimulation produces vasoconstriction.
• Beta-2 stimulation produces bronchodilation.
• Beta-1 stimulation may cause tachycardia.
• Its onset occurs within several minutes.
• Its duration is generally less than two hours.
• A common concentration is 2.25%.
• A typical nebulized dose is 0.25 to 0.5 mL.
• It is strongly associated with croup and postextubation stridor.
• It may help control airway bleeding.
• It is not intended for routine maintenance bronchodilation.
• Symptoms may recur as the medication wears off.
• Severe airway obstruction may require intubation or other definitive airway support.

Racemic Epinephrine Practice Questions

1. What is racemic epinephrine?
Racemic epinephrine is a short-acting adrenergic medication used primarily to reduce upper-airway edema through vasoconstriction.

2. What type of medication is racemic epinephrine?
Racemic epinephrine is an adrenergic, sympathomimetic catecholamine medication.

3. What is the primary respiratory effect of racemic epinephrine?
Its primary respiratory effect is vasoconstriction of swollen airway tissues, which helps reduce mucosal edema.

4. Which adrenergic receptor is primarily responsible for the vasoconstricting effect of racemic epinephrine?
Alpha-1 receptor stimulation is primarily responsible for vasoconstriction.

5. What effect does beta-2 receptor stimulation from racemic epinephrine produce?
Beta-2 receptor stimulation produces relaxation of bronchial smooth muscle and bronchodilation.

6. What effect does beta-1 receptor stimulation from racemic epinephrine produce?
Beta-1 receptor stimulation can increase heart rate and cardiac contractility.

7. Why is racemic epinephrine considered nonselective?
It is considered nonselective because it stimulates alpha, beta-1, and beta-2 adrenergic receptors.

8. What does the term racemic mean in racemic epinephrine?
Racemic refers to a mixture containing two stereochemical forms, or isomers, of epinephrine.

9. Which isomer of racemic epinephrine has significant adrenergic activity?
The R-isomer, also called the levo form, has significant adrenergic activity.

10. What is the usual concentration of racemic epinephrine used for nebulization?
Racemic epinephrine is commonly supplied as a 2.25% solution for nebulization.

11. What is the typical nebulized dose of 2.25% racemic epinephrine?
A typical dose is approximately 0.25 to 0.5 mL of a 2.25% solution.

12. How many milligrams of racemic epinephrine are contained in 0.5 mL of a 2.25% solution?
A 0.5 mL dose contains approximately 11.25 mg of racemic epinephrine.

13. How many milligrams of racemic epinephrine are contained in 0.25 mL of a 2.25% solution?
A 0.25 mL dose contains approximately 5.63 mg of racemic epinephrine.

14. What is the approximate onset of action of nebulized racemic epinephrine?
The onset of action is approximately 3 to 5 minutes.

15. When does racemic epinephrine typically reach its peak effect?
Racemic epinephrine typically reaches its peak effect within approximately 5 to 20 minutes.

16. What is the approximate duration of action of racemic epinephrine?
Its effects generally last approximately 30 minutes to 2 hours.

17. Why does racemic epinephrine have a relatively short duration of action?
It is rapidly metabolized because it is a catecholamine that is susceptible to metabolism by catechol O-methyltransferase.

18. What enzyme contributes to the rapid metabolism of racemic epinephrine?
Catechol O-methyltransferase, or COMT, contributes to its rapid metabolism.

19. What upper-airway disorder in children is commonly treated with racemic epinephrine?
Croup is commonly treated with nebulized racemic epinephrine.

20. Why is racemic epinephrine useful in patients with croup?
It constricts blood vessels in swollen upper-airway tissues, reducing subglottic edema and improving airway diameter.

21. What respiratory sound commonly indicates upper-airway narrowing in croup?
Inspiratory stridor commonly indicates upper-airway narrowing in croup.

22. What characteristic cough is commonly associated with croup?
Croup commonly produces a barking or seal-like cough.

23. What is another major indication for racemic epinephrine following removal of an endotracheal tube?
Postextubation laryngeal edema with stridor is a major indication for racemic epinephrine.

24. How does racemic epinephrine help a patient with postextubation stridor?
It produces vasoconstriction in swollen laryngeal tissues, reducing edema and increasing upper-airway diameter.

25. Why must patients be monitored after receiving racemic epinephrine?
Patients must be monitored because the drug has a short duration of action, symptoms may recur, and cardiovascular effects such as tachycardia and hypertension may occur.

26. What is the main reason racemic epinephrine is preferred over albuterol for upper-airway edema?
Racemic epinephrine provides strong alpha-mediated vasoconstriction, while albuterol primarily produces beta-2-mediated bronchodilation.

27. What type of airway obstruction is most likely to respond to racemic epinephrine?
Upper-airway obstruction caused by mucosal swelling is most likely to respond.

28. What type of respiratory sound is more commonly associated with lower-airway bronchospasm than with upper-airway edema?
Expiratory wheezing is more commonly associated with lower-airway bronchospasm.

29. What is the role of racemic epinephrine in epiglottitis?
It may help reduce laryngeal swelling, but it does not replace careful airway management or intubation when the airway is threatened.

30. Why must airway manipulation be performed cautiously in a patient with epiglottitis?
Manipulation can worsen obstruction in an already severely inflamed upper airway.

31. What bedside medication should be readily available after extubating a patient who was intubated for severe upper-airway inflammation?
Nebulized racemic epinephrine should be readily available.

32. What is the purpose of the cuff-leak test before extubation?
The cuff-leak test helps assess the risk of significant upper-airway edema and postextubation obstruction.

33. What does the presence of an adequate cuff leak generally suggest?
It suggests that air can pass around the endotracheal tube and that significant upper-airway obstruction is less likely.

34. What equipment should be available when extubating a patient at risk for upper-airway obstruction?
Oxygen equipment, suction, a manual resuscitator, reintubation equipment, and nebulized racemic epinephrine should be available.

35. What does decreased air movement after extubation suggest?
It may indicate developing upper-airway obstruction.

36. What is the role of racemic epinephrine in bronchoscopy-related bleeding?
It produces local vasoconstriction that can help reduce bleeding from biopsied airway tissue.

37. Why can racemic epinephrine help control bleeding after an endoscopic airway procedure?
Its alpha-1 activity constricts local blood vessels and decreases blood flow to the bleeding site.

38. How may racemic epinephrine be used before nasotracheal intubation?
It may be applied to the nasal mucosa to decrease swelling and reduce the risk of nasal bleeding.

39. What other topical vasoconstrictor may be used before nasotracheal intubation?
Phenylephrine may also be used.

40. Why is racemic epinephrine not commonly used as a routine maintenance bronchodilator?
Its effects are too short-lived, and its nonselective receptor activity increases the risk of cardiovascular side effects.

41. Which medication is generally preferred over racemic epinephrine for routine lower-airway bronchodilation?
A selective beta-2 agonist such as albuterol is generally preferred.

42. What cardiovascular adverse effect can occur because of beta-1 receptor stimulation?
Tachycardia can occur because of beta-1 receptor stimulation.

43. What cardiovascular adverse effect can occur because of systemic alpha-receptor stimulation?
Increased blood pressure can occur because of vasoconstriction.

44. What neurologic or systemic adverse effects may occur with racemic epinephrine?
Tremor, headache, nervousness, irritability, and insomnia may occur.

45. Why should heart rate be checked before and after racemic epinephrine treatment?
Adrenergic stimulation can significantly increase heart rate and cardiac workload.

46. What general change in pulse rate may indicate that aerosolized adrenergic therapy should be stopped?
An increase of approximately 20% or more above the pretreatment pulse may indicate the need to stop therapy and reassess the patient.

47. What is the role of racemic epinephrine in bronchiolitis?
It may be given as a trial in selected patients with persistent wheezing or respiratory distress, but it should not be used routinely without objective improvement.

48. When should racemic epinephrine be continued in a patient with bronchiolitis?
It should be continued only if there is objective evidence of clinical improvement.

49. Why can symptoms recur after racemic epinephrine initially improves airway swelling?
The medication has a short duration and does not immediately eliminate the underlying inflammatory process.

50. What is the key treatment principle when severe airway obstruction continues despite racemic epinephrine?
Definitive airway support should not be delayed when obstruction remains severe or continues to worsen.

51. Why is racemic epinephrine particularly effective for swollen airway mucosa?
Its alpha-adrenergic activity causes vasoconstriction, which decreases vascular engorgement and tissue edema.

52. How does reducing mucosal edema improve airflow?
Reducing edema increases the functional diameter of the airway and lowers resistance to airflow.

53. Why can relatively small amounts of edema be especially dangerous in children?
Children have smaller airways, so even minor swelling can cause a proportionally greater reduction in airway diameter.

54. What clinical signs may indicate worsening upper-airway obstruction?
Increasing stridor, retractions, decreased air movement, agitation, cyanosis, and altered mental status may indicate worsening obstruction.

55. Why is oxygen saturation alone not enough to assess the severity of upper-airway obstruction?
Significant airway narrowing can progress before oxygen desaturation becomes severe, so work of breathing and air movement must also be assessed.

56. What role do corticosteroids play when racemic epinephrine is used for croup?
Corticosteroids help reduce the underlying airway inflammation and provide a longer-lasting effect than racemic epinephrine.

57. What inhaled corticosteroid may be used in the treatment of croup?
Budesonide may be used to reduce the severity of croup symptoms.

58. Why is racemic epinephrine considered a rapid-relief medication rather than a definitive treatment for croup?
It quickly reduces swelling, but the effect is temporary and does not immediately eliminate the underlying inflammation.

59. What is the significance of stridor occurring at rest in a child with croup?
Stridor at rest suggests more significant upper-airway obstruction and a greater degree of respiratory distress.

60. What does cyanosis in a child with croup indicate?
Cyanosis suggests severe airway obstruction and inadequate oxygenation.

61. What is the steeple sign associated with?
The steeple sign is associated with subglottic airway narrowing in croup.

62. What does the steeple sign represent anatomically?
It represents narrowing of the tracheal air column in the subglottic region.

63. How does epiglottitis differ clinically from croup?
Epiglottitis often presents with high fever, drooling, muffled voice, and severe distress without the typical barking cough of croup.

64. What position may a child with severe epiglottitis assume to help maintain airway patency?
The child may assume a tripod position.

65. Why should reintubation equipment be available when a high-risk patient is extubated?
Upper-airway edema may rapidly worsen, making immediate airway reestablishment necessary.

66. What is one important assessment following extubation in a patient at risk for laryngeal edema?
The patient should be assessed for stridor and adequate air movement.

67. Why may cool humidified oxygen be used with racemic epinephrine after extubation?
It can provide oxygen and humidification while the medication helps reduce airway edema.

68. How is laryngospasm managed differently from postextubation edema?
Laryngospasm may require positive-pressure ventilation, neuromuscular blockade, and reintubation rather than relying on racemic epinephrine alone.

69. What is heliox and when may it be considered with upper-airway obstruction?
Heliox is a helium-oxygen mixture that may be considered when significant airway obstruction persists despite initial therapy.

70. Why can heliox help patients with upper-airway narrowing?
Its low density can reduce turbulent airflow resistance through a narrowed airway.

71. What should be done if a patient with croup develops declining consciousness and respiratory acidosis?
Intubation and mechanical ventilation should be considered because these findings suggest impending or actual respiratory failure.

72. What is the role of racemic epinephrine in inhalation injury?
It may help reduce upper-airway edema caused by smoke, steam, or irritating chemical exposure.

73. Why should racemic epinephrine not delay intubation in a patient with severe inhalation injury?
Airway swelling can progress rapidly, and definitive airway protection may become urgently necessary.

74. Why is aerosol administration useful for racemic epinephrine?
Aerosol delivery places the medication directly on airway tissues, allowing a rapid local effect with less systemic exposure than injection.

75. What is the major clinical advantage of racemic epinephrine over a selective beta-2 agonist?
Its alpha-mediated vasoconstricting effect allows it to reduce airway edema in addition to producing some bronchodilation.

76. Why can racemic epinephrine temporarily improve airway caliber?
It decreases blood flow to swollen mucosal tissue, which reduces edema and enlarges the airway lumen.

77. What type of drug effect makes racemic epinephrine useful in airway bleeding?
Its local vasoconstricting effect makes it useful for reducing bleeding.

78. Why is racemic epinephrine considered less selective than albuterol?
Racemic epinephrine stimulates alpha, beta-1, and beta-2 receptors, while albuterol primarily targets beta-2 receptors.

79. What is one reason racemic epinephrine can increase myocardial workload?
Beta-1 stimulation can increase heart rate and force of contraction.

80. Why should blood pressure be monitored during racemic epinephrine therapy?
Alpha-mediated vasoconstriction can contribute to an increase in blood pressure.

81. What does a 2.25% racemic epinephrine solution contain per milliliter?
A 2.25% solution contains 22.5 mg of racemic epinephrine per mL.

82. How much racemic epinephrine is present in 0.6 mL of a 2.25% solution?
A 0.6 mL dose contains 13.5 mg of racemic epinephrine.

83. Why is racemic epinephrine generally not administered orally?
Catecholamines are rapidly metabolized in the gastrointestinal tract and liver, making oral administration ineffective.

84. What routes are commonly used to administer epinephrine-based medications when a rapid effect is needed?
Inhalation and injection are commonly used because they provide a more reliable and rapid effect than oral administration.

85. Why can racemic epinephrine be useful before nasotracheal intubation?
It can reduce nasal mucosal swelling and decrease the likelihood of bleeding during tube insertion.

86. What is the main difference between aerosolized racemic epinephrine and systemic epinephrine in anaphylaxis?
Aerosolized racemic epinephrine primarily provides local airway vasoconstriction, while systemic epinephrine treats widespread airway and cardiovascular effects.

87. Why is systemic epinephrine required when anaphylaxis causes hypotension?
Systemic epinephrine increases vascular tone and supports blood pressure in addition to treating airway involvement.

88. What does persistent stridor after racemic epinephrine suggest?
Persistent stridor suggests that significant upper-airway obstruction remains and additional respiratory support may be necessary.

89. Why is repeated assessment important after an apparently successful racemic epinephrine treatment?
The drug’s effect is short-lived, so airway swelling and respiratory distress can return after initial improvement.

90. What does worsening air movement with increasing stridor indicate?
It indicates progression of upper-airway obstruction and the need for urgent reassessment.

91. Why is racemic epinephrine not appropriate for a fixed mechanical airway obstruction?
Vasoconstriction cannot remove a fixed obstruction such as a foreign body.

92. What is the primary therapeutic target of racemic epinephrine in postextubation stridor?
The primary target is swollen laryngeal mucosa.

93. How can agitation affect a child with significant croup?
Agitation can increase respiratory effort and worsen stridor and retractions.

94. Why should clinicians try to minimize unnecessary agitation in a child with upper-airway obstruction?
Keeping the child calm can help reduce oxygen demand and prevent worsening of respiratory distress.

95. What does progressive cyanosis in upper-airway obstruction suggest?
Progressive cyanosis suggests severe impairment of airflow and inadequate oxygenation.

96. What chemical process can cause racemic epinephrine solution residue to become pink or pinkish-brown?
Oxidation of the catecholamine can form adrenochrome compounds that produce the discoloration.

97. Why is racemic epinephrine commonly stored in an amber-colored container or protected from light?
Light can accelerate degradation of the catecholamine and reduce drug stability.

98. What environmental factors can contribute to degradation of racemic epinephrine?
Heat, light, and air can contribute to its chemical degradation.

99. Why might pink-tinged condensate after nebulized racemic epinephrine not indicate bleeding?
The discoloration may result from oxidation of epinephrine to adrenochrome rather than the presence of blood.

100. What is the central clinical principle to remember about racemic epinephrine?
Racemic epinephrine is a rapid, short-acting adrenergic medication used mainly to reduce upper-airway edema through vasoconstriction, while continued monitoring remains necessary because symptoms can recur.

Final Thoughts

Racemic epinephrine is a rapid-acting adrenergic medication used primarily to reduce upper-airway swelling through alpha-mediated vasoconstriction. Its most recognized applications include croup, postextubation laryngeal edema, stridor, selected inhalation injuries, and localized airway bleeding.

Although the medication also stimulates beta receptors and can produce bronchodilation, its ability to reduce mucosal edema distinguishes it from selective beta-2 agonists such as albuterol.

Because its effects are relatively short-lived, patients require continued assessment after treatment. Persistent or worsening airway obstruction should prompt escalation of respiratory support and definitive airway management when necessary.